702489
antibody from Invitrogen Antibodies
Targeting: RUNX2
AML3, CBFA1, CCD, CCD1, PEBP2A1, PEBP2aA1
Antibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Western blot [3]
- Other assay [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 702489 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- RUNX2 Recombinant Rabbit Monoclonal Antibody (6H4L27)
- Antibody type
- Monoclonal
- Antigen
- Other
- Reactivity
- Human
- Host
- Rabbit
- Isotype
- IgG
- Antibody clone number
- 6H4L27
- Vial size
- 100 µg
- Concentration
- 0.5 mg/mL
- Storage
- Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
Submitted references High glucose inhibits the osteogenic differentiation of periodontal ligament stem cells in periodontitis by activating endoplasmic reticulum stress.
Tan J, Zhou Y, Luo J, Wu X, Liu H, Wang W, Li Z, Zhong M, Wu L, Li X
Annals of translational medicine 2022 Feb;10(4):204
Annals of translational medicine 2022 Feb;10(4):204
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Knockdown of RUNX2 was achieved by transfecting MD-AMB-231 cells with RUNX2 specific siRNA (Silencer® select Product # s2455 and Product # s2457). Western blot analysis (Fig a) was performed using modified whole cell extracts (1% SDS) from RUNX2 knockdown cells (Lane 3), non-specific scrambled siRNA transfected cells (Lane 2) and untransfected cells (Lane 1). The blot was probed with Anti-RUNX2 Recombinant Rabbit Monoclonal Antibody (Product # 702489, 1:400 dilution) and Goat anti-Rabbit IgG (H+L) Superclonal™ Secondary Antibody, HRP conjugate (Product # A27036, 0.25 µg/mL, 1:4000 dilution). Densitometric analysis of this Western blot is shown in histogram (Fig b). Loss of signal upon siRNA mediated knock down confirms that antibody is specific to RUNX2.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis was performed on whole cell extracts (30 µg lysate) of differentiated osteoblasts from Human bone marrow derived mesenchymal stem cells at different stages such as Day 0 (Lane 1), Day 7 (Lane 2) and Day 14 (Lane 3) along with U-2 OS (Lane 4). The invitro osteogenesis differentiation was performed using StemPro™ Osteogenesis Differentiation Kit, (Product # A1007201) as per the manufacturer instructions. The blots were probed with Anti-RUNX2 Recombinant Rabbit Monoclonal Antibody (Product # 702489, 1:200 dilution) and detected by chemiluminescence using Goat anti-Rabbit IgG (H+L) Superclonal™ Secondary Antibody, HRP conjugate (Product # A27036,1:4000 dilution). A~ 56 kDa band corresponding to RUNX2 was observed in U-2 OS cells and in early differentiation stages (Day 7).
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of RUNX2 was performed by loading whole-cell lysate of human osteosarcoma cell line 17-3X. RUNX2 was detected at approximately 60 kDa using a RUNX2 Monoclonal Antibody (Product # 702489) at a dilution of 1:1000 in Blocking Buffer (Product # 37543) overnight at 4°C on a rocking platform, followed by a 1-hour room-temperature incubation of a goat anti-rabbit IgG antibody at a dilution of 1:5000. Data courtesy of Thermo Scientific KOL Program.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- The effects of GRP78 shRNA on the osteogenic differentiation ability of PDLSCs under different glucose concentrations. (A) The mRNA expression levels of osteogenic factors after 7-day osteogenic induction. (B) Comparison of the total optical density values of ALP positive staining in each group. ALP staining of PDLSCs after osteogenic induction in 8 mmol/L D-glucose + NC (control group) (C), 8 mmol/L D-glucose + GRP78 shRNA lentivirus (D), 25 mmol/L D-glucose + NC (E), and 25 mmol/L D-glucose + GRP78 shRNA lentivirus (F). (G) The protein levels of osteogenic factors, as detected by western blot. (H) Quantification of osteogenic factor protein expression, using beta-actin for internal reference. Alizarin red staining of PDLSCs after osteogenic induction in 8 mmol/L D-glucose + NC (control group) (I), 8 mmol/L D-glucose + GRP78 shRNA lentivirus (J), 25 mmol/L D-glucose + NC (K), and 25 mmol/L D-glucose + GRP78 shRNA lentivirus (L). (M) Comparison of the total optical density values of alizarin red positive staining. Bar =100 um. *, P
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- The osteogenic differentiation abilities of PDLSCs cultured in osteogenic inducing medium containing D-glucose at different concentrations. ALP staining of PDLSCs after osteogenic induction in 5.6 mmol/L D-glucose (control group) (A), 8 mmol/L D-glucose (B), 11 mmol/L D-glucose (C), and 25 mmol/L D-glucose (D). (E) Comparison of the total optical density values of ALP positive staining in each group. (F) The protein levels of Runx2 and OCN were detected by western blot after 2-week osteogenic induction at different D-glucose concentrations. (G) Quantification of Runx2 and OCN protein expression. The relative quantities evaluated by band grey value were normalized to beta-actin and are presented as mean +- SD. (H) Comparison of the total optical density values of alizarin red staining. Alizarin red staining of PDLSCs after osteogenic induction in 5.6 mmol/L D-glucose (control group) (I), 8 mmol/L D-glucose (J), 11 mmol/L D-glucose (K), and 25 mmol/L D-glucose (L). Bar =100 um. *, P